Welcome To Campus Sanofi Thailand

In this issue, we feature three studies that provide insights into disease modification in atopic dermatitis, examining microbiome restoration, long-term infection outcomes in real-world practice, and clinical responses in erythrodermic presentations.

We are pleased to share with you information on ‘Safety and Efficacy of Treatment with Dupilumab for up to 2 Years in Infants and Young Children with Atopic Dermatitis,’ together with the ‘Guidelines of Care for the Management of Atopic Dermatitis in Pediatric Patients.’ We believe these publications may be of interest to you.

This email highlights key evidence regarding dupilumab, including its long-term safety and efficacy profile in infants and young children with atopic dermatitis. It also presents current guideline recommendations, which strongly support the use of dupilumab in children aged 6 months and older with moderate-to-severe atopic dermatitis.

Curated evidence on atopic dermatitis, organised around the four disease-modification pillars — starting with new data on skin-barrier restoration in children.

Curated June evidence on atopic dermatitis, organised around the four disease-modification pillars — starting with new data on skin-barrier restoration in children

I am pleased to share information regarding the Biologics in Atopic Dermatitis: Effectiveness, Safety, and Future Directions, which you may find of interest. In this email, you will find the key highlights on dupilumab for long-term disease management in atopic dermatitis.

Explore ATS 2026 key sessions on dupilumab, COPD biologics, FeNO biomarkers, and asthma remission. Real-world evidence for HCPs